InsidersTradesSigma
Total declarations
Companies
▲ Purchases (24 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by WHITMAN BURKE W, Director. Insider active across 2 companies, notably Amicus Therapeutics, INC.. In total, 30 filings have been logged. Total volume traded: €316k. The latest transaction was filed on 9 June 2022 — Attribution. Regulator: SEC (Form 4). The full history is free.
Declarations30 total
012,671 shares0
Common Stock
SEC:0001209191-22-035862:0·
€139,5025,131 shares@ €27.1880.0011% mcap26.0% of flow
Common Stock
SEC:0001415889-22-006173:0·
€13,6151,500 shares@ €9.0770.0003% mcap18.0% of flow
Common Stock
SEC:0001209191-21-062795·
Ideal exit: 29 Jul 2022 (T+270)
€13,6151,500 shares@ €9.0770.0003% mcap8.3% of flow
Common Stock
SEC:0001209191-21-062795:0·
Ideal exit: 29 Jul 2022 (T+270)
€12,3951,500 shares@ €8.2630.0003% mcap16.4% of flow
Common Stock
SEC:0001209191-21-059153·
Ideal exit: 28 Jun 2022 (T+270)
€12,3951,500 shares@ €8.2630.0003% mcap7.6% of flow
Common Stock
SEC:0001209191-21-059153:0·
Ideal exit: 28 Jun 2022 (T+270)
€14,4541,500 shares@ €9.63610.0003% mcap19.1% of flow
Common Stock
SEC:0001209191-21-055057·
Ideal exit: 29 May 2022 (T+270)
€14,4541,500 shares@ €9.63610.0003% mcap8.8% of flow
Common Stock
SEC:0001209191-21-055057:0·
Ideal exit: 29 May 2022 (T+270)
€14,209500 shares@ €28.41840.0001% mcap7.1% of flow
Common Stock
SEC:0001127602-21-024647·
Ideal exit: 29 May 2022 (T+270)
€14,209500 shares@ €28.41840.0001% mcap2.6% of flow
Common Stock
SEC:0001127602-21-024647:0·
Ideal exit: 29 May 2022 (T+270)
€11,7221,500 shares@ €7.8150.0003% mcap15.5% of flow
Common Stock
SEC:0001209191-21-049703·
Ideal exit: 29 Apr 2022 (T+270)
€11,7221,500 shares@ €7.8150.0003% mcap7.1% of flow
Common Stock
SEC:0001209191-21-049703:0·
Ideal exit: 29 Apr 2022 (T+270)
€15,369500 shares@ €30.73770.0001% mcap7.7% of flow
Common Stock
SEC:0001127602-21-022727·
Ideal exit: 29 Apr 2022 (T+270)
€15,369500 shares@ €30.73770.0001% mcap2.9% of flow
Common Stock
SEC:0001127602-21-022727:0·
Ideal exit: 29 Apr 2022 (T+270)
€12,1561,500 shares@ €8.10380.0003% mcap16.1% of flow
Common Stock
SEC:0001209191-21-046712·
Ideal exit: 28 Mar 2022 (T+270)
€12,1561,500 shares@ €8.10380.0003% mcap7.4% of flow
Common Stock
SEC:0001209191-21-046712:0·
Ideal exit: 28 Mar 2022 (T+270)
€15,321500 shares@ €30.64260.0001% mcap7.7% of flow
Common Stock
SEC:0001127602-21-020924·
Ideal exit: 28 Mar 2022 (T+270)
€15,321500 shares@ €30.64260.0001% mcap2.9% of flow
Common Stock
SEC:0001127602-21-020924:0·
Ideal exit: 28 Mar 2022 (T+270)
010,115 shares0
Common Stock
SEC:0001209191-21-040381·
010,115 shares0
Common Stock
SEC:0001209191-21-040381:0·
€123,0013,949 shares@ €31.14740.0009% mcap61.9% of flow
Common Stock
SEC:0001127602-21-019505·
€123,0013,949 shares@ €31.14740.0009% mcap22.9% of flow
Common Stock
SEC:0001127602-21-019505:0·
€11,3451,500 shares@ €7.56340.0002% mcap15.0% of flow
Common Stock
SEC:0001209191-21-037394·
Ideal exit: 26 Feb 2022 (T+270)
€11,3451,500 shares@ €7.56340.0002% mcap6.9% of flow
Common Stock
SEC:0001209191-21-037394:0·
Ideal exit: 26 Feb 2022 (T+270)
€15,126500 shares@ €30.2510.0001% mcap7.6% of flow
Common Stock
SEC:0001127602-21-018398·
Ideal exit: 26 Feb 2022 (T+270)
25 of 30 declarations
About WHITMAN BURKE W
Burke W. Whitman is a U.S. corporate and nonprofit director best known for board service in healthcare and governance roles. He has served on the board of Amicus Therapeutics since 2019 and on the board of Omega Healthcare Investors since 2018. At Amicus, he serves on the Nominating and Corporate Governance Committee and the Audit and Compliance Committee, reflecting a profile centered on oversight, financial discipline, and board effectiveness. His career combines senior healthcare executive experience with a long military service record. Prior to joining Amicus, Whitman served as President and Chief Executive Officer, and as a director, of Health Management Associates, a publicly traded hospital operator. In that role, he was recognized by Institutional Investor magazine as a Best CEO in 2008. From 1998 to 2005, he served as Chief Financial Officer of Triad Hospitals, another publicly traded hospital company, and was twice named a Best CFO by Institutional Investor. Earlier in his business career, he held leadership positions at Deerfield Healthcare and Almost Family, and he also worked as an investment banker at Morgan Stanley. Whitman’s executive background is complemented by distinguished service in the United States Marine Corps Reserve, where he rose to the rank of major general. His military career included leadership of the Marine Forces Reserve and the 4th Marine Division, along with service in roles connected to the Secretary of Defense. This combination of corporate leadership and military command has shaped his reputation as a disciplined, mission-oriented leader with strong strategic and operational judgment. He has also contributed to civic and defense-related organizations, including the Marine Corps Heritage Foundation, the Reserve Forces Policy Board, the Federation of American Hospitals, Toys for Tots Foundation, and The Lovett School. Whitman holds an MBA from Harvard Business School, a Master of Strategic Studies from the U.S. Army War College, and a BA from Dartmouth College. Across his board and executive roles, he brings expertise in finance, healthcare operations, strategy, risk oversight, and corporate governance.
